Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 10:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 3,472 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Healthy Adults Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Evaluate the Relative Bioavailability, Food Effect, and Dose Proportionality of a Granule Formulation of Vanzacaftor/Tezacaftor/Deutivacaftor(VNZ/TEZ/D-IVA)

NCT06299709
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VNZ/TEZ/D-IVA
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 26, 2025 · Synced Oct 18, 2026, 10:46 AM EDT
Terminated Not applicable Interventional

Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women

NCT04556032
View directory record Official record
Conditions
Healthy
Interventions
L-Ergothioneine 10 mg/d, L-Ergothioneine 25 mg/d, Placebo
Dietary Supplement · Other
Lead sponsor
Midwest Center for Metabolic and Cardiovascular Research
Other
Eligibility
55 Years to 79 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 4, 2020 · Synced Oct 18, 2026, 10:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of the Cardiac Effects of ALXN1840 in Healthy Adults

NCT04560816
View directory record Official record
Conditions
Healthy
Interventions
ALXN1840, Placebo, Moxifloxacin
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Oct 18, 2026, 10:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Safety and Efficacy of a Single Dose of a Dengue Vaccine (TV005) in Healthy Adults

NCT02317900
View directory record Official record
Conditions
Dengue
Interventions
TV005, Placebo, rDEN2∆30-7169
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2014
U.S. locations
2
States / cities
Baltimore, Maryland • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Feb 1, 2017 · Synced Oct 18, 2026, 10:46 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Study to Evaluate the Safety and the Immunogenicity of a Second Generation Structurally Designed mRNA Vaccine Candidate Against Pandemic Influenza H5 HA Strain in Healthy Adult Participants Aged 18 Years and Older

NCT06907511
View directory record Official record
Conditions
Pandemic Influenza Immunization, Healthy Volunteers
Interventions
Pandemic flu H5 HA mRNA SD2 vaccine, Placebo
Biological · Other
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
720 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
13
States / cities
La Mesa, California • DeLand, Florida • Lakeland, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2026 · Synced Oct 18, 2026, 10:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Comparison of VR647 and Conventionally Nebulized Budesonide in Healthy Volunteers and Adult Asthma Subjects

NCT04032834
View directory record Official record
Conditions
Asthma
Interventions
VR647 Inhalation Suspension (budesonide) 1 mg/2 mL delivered by the VR647 Inhalation System (AKITA JET) with mouthpiece, VR647 Inhalation Suspension (budesonide) 1 mg/2 mL delivered by the VR647 Inhalation System (AKITA JET) with facemask, 1 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer (PARI VIOS) with mouthpiece, 1 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer (PARI VIOS) with facemask, 0.5 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer (PARI VIOS) with mouthpiece, 0.5 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer (PARI VIOS) with facemask
Combination Product
Lead sponsor
Vectura Limited
Industry
Eligibility
18 Years to 55 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
2
States / cities
Tempe, Arizona • Anaheim, California
Source: ClinicalTrials.gov public record
Updated Jul 25, 2019 · Synced Oct 18, 2026, 10:46 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Food Trial to Evaluate the Safety and Tolerability of SBD111 in Health Adults

NCT05206864
View directory record Official record
Conditions
Healthy
Interventions
Medical Food: SBD111, Placebo
Other
Lead sponsor
Solarea Bio, Inc
Industry
Eligibility
18 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 13, 2022 · Synced Oct 18, 2026, 10:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

BT-600 Single and Multiple Ascending Oral Doses in Healthy Adult Subjects

NCT06275464
View directory record Official record
Conditions
Healthy
Interventions
BT-600, BT-600 Placebo
Combination Product
Lead sponsor
Biora Therapeutics, Inc.
Industry
Eligibility
19 Years to 50 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Nov 21, 2024 · Synced Oct 18, 2026, 10:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Drug Levels, Metabolism, and Removal of BMS-986322 in Healthy Adult Male Participants

NCT06088264
View directory record Official record
Conditions
Healthy Male Participants
Interventions
BMS-986322
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 29, 2024 · Synced Oct 18, 2026, 10:46 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study of BPZE1 Intranasal Pertussis Vaccine (Administered Via VaxINator(TM)), Prime + Boost, in Healthy Adults

NCT03942406
View directory record Official record
Conditions
Pertussis, Whooping Cough
Interventions
BPZE1 pertussis vaccine and VaxINator(TM) Atomization Device
Combination Product
Lead sponsor
ILiAD Biotechnologies
Industry
Eligibility
18 Years to 50 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
3
States / cities
Cleveland, Ohio • Tomball, Texas • West Jordan, Utah
Source: ClinicalTrials.gov public record
Updated Jun 27, 2023 · Synced Oct 18, 2026, 10:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to Two HIV Vaccines: SAAVI DNA-C2 Boosted With SAAVIMVA-C, in HIV-Negative Adults

NCT00574600
View directory record Official record
Conditions
HIV Infections
Interventions
SAAVI DNA-C2 vaccine, SAAVI MVA-C vaccine, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Oct 18, 2026, 10:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Understand the Effect of Multiple Ascending Doses of PF-07293893 in Healthy Adult Participants

NCT06177457
View directory record Official record
Conditions
Healthy Participants
Interventions
PF-07293893, Placebo, Midazolam
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
2
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 18, 2024 · Synced Oct 18, 2026, 10:46 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Blood Collection In Healthy Adult Volunteers To Obtain Serum For Use In Serum Bactericidal Activity Assay Development

NCT00401232
View directory record Official record
Conditions
Healthy Subjects
Interventions
Blood Collection
Procedure
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 64 Years
Enrollment
955 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2017
U.S. locations
2
States / cities
Baltimore, Maryland • Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 19, 2018 · Synced Oct 18, 2026, 10:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Trial to Evaluate the Effects of Itraconazole and Carbamazepine on the Pharmacokinetics of Emraclidine and of Emraclidine on the Pharmacokinetics of Metformin in Healthy Adult Participants

NCT05965219
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Emraclidine, Itraconazole, Carbamazepine, Metformin
Drug
Lead sponsor
Cerevel Therapeutics, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 2, 2024 · Synced Oct 18, 2026, 10:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of ALKS 8700, a Monomethyl Fumarate (MMF) Molecule, in Healthy Adults

NCT02201849
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Study Drug, Active Control, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 26, 2019 · Synced Oct 18, 2026, 10:46 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate Safety, Tolerability, and Pharmacokinetics of Oral AZD0233 Compared With Placebo in Healthy Adult Participants.

NCT06381466
View directory record Official record
Conditions
Dilated Cardiomyopathy
Interventions
AZD0233, AZD0233 Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 50 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Oct 18, 2026, 10:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

To Study the Oral Bioavailability of a New Combination Formation of Decitabine and Tetrahydrouridine in Healthy Males

NCT05816356
View directory record Official record
Conditions
Healthy
Interventions
Decitabine, Tetrahydrouridine
Drug
Lead sponsor
EpiDestiny, Inc.
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 22, 2025 · Synced Oct 18, 2026, 10:46 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Does Overpractice Improve Motor Learning?

NCT02898701
View directory record Official record
Conditions
Aging
Interventions
Motor Practice of a Standing Serial Reaction Time Task
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 95 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 15, 2021 · Synced Oct 18, 2026, 10:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability and Pharmacokinetics of FTX-6058

NCT04586985
View directory record Official record
Conditions
Healthy Adult Subjects, Sickle Cell Disease
Interventions
FTX-6058/placebo oral capsule(s), FTX-6058 - Two Dosing Periods, FTX-6058 / Midazolam Syrup
Drug
Lead sponsor
Fulcrum Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
109 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
2
States / cities
Atlanta, Georgia • Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 12, 2022 · Synced Oct 18, 2026, 10:46 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

First in Human Dose Escalation Study Evaluating the Safety and Immunogenicity of IVT's Shigella-04 Vaccine in Healthy Young Adults

NCT07205926
View directory record Official record
Conditions
Shigella, Diarrhea
Interventions
IVT Shigella-04, Placebo (0.9% saline)
Biological
Lead sponsor
Inventprise Inc.
Industry
Eligibility
18 Years to 49 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 19, 2025 · Synced Oct 18, 2026, 10:46 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Study to Evaluate MEDI-534 in Healthy Adults

NCT00111878
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections, Parainfluenza Infections
Interventions
MEDI-534
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 40 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
3
States / cities
Columbus, Ohio • Pittsburgh, Pennsylvania • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 3, 2007 · Synced Oct 18, 2026, 10:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of PRTX-100 in Healthy Adult Volunteers

NCT00517855
View directory record Official record
Conditions
Healthy Volunteers
Interventions
PRTX-100 (Staphylococcal protein A)
Biological
Lead sponsor
Protalex, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated May 6, 2008 · Synced Oct 18, 2026, 10:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Investigate A Clostridium Difficile Vaccine In Healthy Adults Aged 50 To 85 Years, Who Will Each Receive 3 Doses Of Vaccine.

NCT02052726
View directory record Official record
Conditions
Clostridium Difficile
Interventions
C. difficile vaccine with adjuvant, placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
50 Years to 85 Years
Enrollment
184 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
6
States / cities
Overland Park, Kansas • Cary, North Carolina • Raleigh, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2018 · Synced Oct 18, 2026, 10:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Relative Bioavailability Study Evaluating Two New Encorafenib Formulations

NCT05446142
View directory record Official record
Conditions
Healthy
Interventions
Encorafenib capsule formulation (CAP), Encorafenib first formulation, Encorafenib second formulation, Rabeprazole tablet
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 23, 2024 · Synced Oct 18, 2026, 10:46 AM EDT